Correction: Vassallo et al. Hyaluronic Acid-Based Injective Medical Devices: In Vitro Characterization of Novel Formulations Containing Biofermentative Unsulfated Chondroitin or Extractive Sulfated One with Cyclodextrins. Pharmaceuticals 2023, 16, 1429

In the original publication [1], there were mistakes in Figure 1 caption and the location of some software companies.

1. Error in Figure 1 Caption

Chondroitin sulfated should be chondroitin sulfate.

The corrected “Figure 1 caption” appears below.

Figure 1. Mechanical spectra of the preparations as commercialized. HHA + CS + cd: hyaluronic acid sodium salt 2% (w/v), marine chondroitin sulfate 2% (w/v), and cyclodextrins 1% (w/v); HHA/BC: hyaluronic acid sodium salt 2.4% (w/v) and unsulfated chondroitin 1.6% (w/v).

2. Errors in Software Company Locations

IBSA Farmaceutici (Lodi, CA, USA) should be IBSA Farmaceutici, Lodi, Italy; Kolinpharma (Lodi, CA, USA) (Kolinpharma) should be Kolinpharma, Milan, Italy; BD Falcon (BD, Falcon, USA) should be BD, Falcon, Franklin Lakes, NJ, USA; Bio-Rad (Beckman, Milano, Italy) should be Beckman, Milan, Italy; Company (Bio-Rad, Milan, Laboratories) should be Bio-Rad Laboratories, Milan, Italy; Thermo Fisher Scientific (ThermoFisher Scientific, USA) should be Thermo Fisher Scientific, Waltham, MA, USA.

The corrected contents appears below.

Paragraphs 1 and 2 of Section 4.1. Class III Medical Device Based on HA and CS or BC:

Sinogel^® 3 mL (IBSA Farmaceutici, Lodi, Italy) (here referred to as HHA/BC) was kindly provided by IBSA Farmaceutici Italia.

Dolatrox^® (Kolinpharma, Milan, Italy) (here referred to as HHA + CS + cd) was bought in a pharmacy; it is reported to contain hyaluronic acid sodium salt 2% (w/v), chondroitin sulfate 2% (w/v), and cyclodextrins 1% (w/v).

Paragraphs 1 of Section 4.4. OA In Vitro Model Setup:

The next day, the cell suspension was filtered (70 μm, BD Falcon, Franklin Lakes, NJ, USA), centrifuged at 1500 rpm for 7 min (Eppendorf Centrifuge), washed with PBS, and re-centrifuged.

Paragraphs 1 of Section 4.5. Cellular Viability Assay:

The optical densities of the supernatants were measured at 450 nm using a Beckman DU 640 spectrometer (Beckman, Milan, Italy) after specific treatments and incubation with a cell counting solution.

Paragraphs 1 of Section 4.6. Gene Expression Analyses via qRT-PCR:

The variation of gene expression was calculated by normalizing the data about GAGs treated cells with respect to pCTRL, applying the Livak method (2^−ΔΔCt) [55] and using Bio-Rad iQ™5 Optical System Software, Version 2.1 (Bio-Rad Laboratories, Milan, Italy).

Paragraphs 1 of Section 4.7. Protein Analyses via Western Blotting:

Primary chondrocytes were seeded in a 12-well standard plate (BD Falcon, Franklin Lakes, NJ, USA) (30 × 10³ cells/well) and in vitro cultivated in the presence or not (pCTRL) of GAGs-based gels for 7 days at a final concentration in the culture medium of 4 mg/mL.

Paragraphs 1 of Section 4.8. Immunofluorescence Analyses:

To analyze the protein expression of COLII via immunofluorescence staining (IF), primary chondrocytes were seeded in a chamber slide (BD Falcon, Franklin Lakes, NJ, USA) (5 × 10³ cells/well) and in vitro cultivated in the presence or not (pCTRL) of GAG-based medical devices (4 mg/mL) for 24 h.

Then, the slices were incubated with a FITC-conjugated goat anti-rabbit secondary antibody (Thermo Fisher Scientific, Waltham, MA, USA) (diluted 1:200) for 1 h at room temperature and covered using the mounting medium with DAPI-aqueous.

Paragraphs 1 of Section 4.9. ELISA Assay:

Each experiment was performed in triplicate, and the cytokine was quantified by a microplate reader (Bio-Rad Laboratories, Milan, Italy).

The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.